findmyKOL
Clinical trialNCT07250087RecruitingPhase 1Interventional

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment36Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults: one group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Aleksandr Lazaryan, MDAsmita Mishra, MDBijal Shah, MDCiara Freeman, MDDoris Hansen, MDFabiana Perna, MDFarhad Khimani, MDFrederick Locke, MDHien Liu, MDJoseph Pidala, MDLia Perez, MDMelissa Alsina, MDMichael Jain, MDNancy Torres Luna, MDNelli Bejanyan, MDOmar Castaneda Puglianini, MDRawan Faramand, MDReshma Ramlal, MDSayeef Mirza, MDTaiga Nishihori, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Asciminib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Jan 2026
Primary completion
30 Nov 2029
Completion
30 Nov 2029
Last update posted
27 Mar 2026
Registered enrollment
36
Registry id
NCT07250087
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.